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Abstract  Pompe  disease  is  a  rare  autosomal  recessive  neuromuscular  disorder  caused  by  acid
-glucosidase  enzyme  (GAA)  deficiency  and  divided  into  two  distinct  variants,  infantile-  and
late-onset. The  late-onset  variant  is characterized  by  a  spectrum  of  phenotypic  variation  that
may range  from  asymptomatic,  to  reduced  muscle  strength  and/or  diaphragmatic  paralysis.
Since muscle  strength  loss  is  characteristic  of  several  different  conditions,  which  may  also
cause diaphragmatic  paralysis,  a  protocol  was  created  to  search  for  the  diagnosis  of  Pompe
disease  and  exclude  other  possible  causes.
Methods:  We  collected  a  sample  size  of 18  patients  (10 females,  8 males)  with  a  median  age
of 60  years  and diagnosis  of  diaphragmatic  paralysis  of  unknown  etiology,  followed  in the  Pul-
monology  outpatient  consultation  of  9 centers  in Portugal,  over  a  24-month  study  period.  We
evaluated data  from  patient’s  clinical  and  demographic  characteristics  as  well  as  complemen-
tary diagnostic  tests  including  blood  tests,  imaging,  neurophysiologic  and respiratory  function
evaluation. All  patients  were  evaluated  for  GAA  activity  with  DBS  (dried  blood  test)  or serum
quantification  and  positive  results  confirmed  by  serum  quantification  and  sequencing.
Results: Three  patients  were  diagnosed  with  Pompe’s  disease  and recommended  for  enzyme
replacement  therapy.  The  prevalence  of  Pompe,  a  rare  disease,  in  our  diaphragmatic  paralysis
patient  sample  was  16.8%.
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Conclusion:  We  conclude  that  DBS  test  for  GAA activity  should  be  recommended  for  all  patients
with diaphragmatic  paralysis  which,  despite  looking  at all  the  most  common  causes,  remains
of unknown  etiology;  this  would  improve  both  the  timing  and  accuracy  of diagnosis  for  Pompe
disease  in this  patient  population.  Accurate  diagnosis  will  lead  to  improved  care  for  this rare,
progressively  debilitating  but  treatable  neuromuscular  disease.
© 2017  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is an
open access  article  under  the  CC BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
Pompe  disease  is  a rare  autosomal  recessive  neuromuscular
disorder  caused  by  acid  -glucosidase  enzyme  (GAA)  defi-
ciency,  resulting  in  the accumulation  of glycogen  in the
lysosomes  of  numerous,  but  primarily  muscular,  tissues.1 It
is  often  termed  glycogen  storage  disease  type  II (GSDII)  or
acid  maltase  deficiency.2,3
Depending  on  the age  of onset,  Pompe  is divided  into
infantile  and late-onset4 disease.  Infantile  onset Pompe  dis-
ease  represents  the  most  severe  form  and  almost  invariably
leads  to  death,  due  to  cardio-respiratory  failure,  within
one  year.  The  late-onset  variant  presents  at  any  time  after
the  age  of  one  year,  and  is  characterized  by a spectrum
of  phenotypic  variation.  It may  range  from  asymptomatic
patients  with  increased  creatine  kinase  (CK)  to  muscle
cramps  and  pain  syndrome  or  rigid-spine  syndrome.5--7 The
lower  limbs  and  paraspinal  muscles  are frequently  affected
first,  followed  by  the respiratory  muscles,  particularly  the
diaphragm,  intercostal  and  accessory  muscles.  Respira-
tory  failure  is  the  main  cause  of  increased  morbidity  and
mortality8,9 and  the  main  cause  of  respiratory  failure  is  dia-
phragmatic  weakness.10
The  diaphragm  is  the major  muscle  of  ventilation  consti-
tuted  by  a  dome-shaped  structure  of  tendons  and muscle
innervated  by  the phrenic  nerves  which  provide  sensory,
sympathetic  and  motor  function.  Diaphragm  contraction
expands  the  chest  increasing  pleural  negative  pressure
and  promoting  air  flow  into  the lungs.  Whenever  there  is
diaphragmatic  weakness  the diaphragm  fails  to  contract
appropriately,  causing reduced  inspiratory  volume  and pos-
sible  dyspnea.  An  extreme  form  of  diaphragmatic  weakness
is  unilateral  or  bilateral  diaphragmatic  paralysis.11 Several
different  conditions  may  present  with  respiratory  failure
and  distinguishing  among them  is  important  to  determine
the  correct  therapeutic  options.12 Pompe  disease  is  in the
differential  diagnosis  of  a wide  variety  of myopathies,
and  therefore  accurate  diagnostic  tools are  needed  for
an  effective  screening  of  this  condition.  Particularly  when
the  progressive  involvement  and  weakness  of  respiratory
muscles  and  diaphragm,  characteristic  of  the disease,  are
closely  related  to  respiratory  dysfunction  which  affects
sleep,  daily  life  activities,  and overall  quality  of  life.
The prevalence  of  this condition  in the  general  pop-
ulation  is unknown,  and varies  according  to  clinical
presentation  and  ethnicity.  The  late-onset  form  has  an esti-
mated  incidence  of  1/57  000.13 In Portugal,  there  is  no
accurate  data  on  the prevalence  of  Pompe  disease,  but  it is
estimated  that there  are 27  cases of  patients  under  enzyme
replacement  therapy  (ERT).14--16
Therefore,  the primary  objective  of  this  study  was  to
estimate  the prevalence  of  this  disorder  in  patients  with
a  diagnosis  of diaphragmatic  paralysis  of unknown  etiology
followed  in the outpatient  setting  of a  Pulmonology  clinic,
and  to  characterize  the clinical  and  socio-demographic
profile  of  these  patients.  A secondary  objective  was  to  cre-
ate  an algorithm  for the accurate  diagnosis of  late-onset
Pompe  disease  in  patients  with  diaphragmatic  paralysis
of  unknown  etiology,  which  will  lead  to  better  manage-
ment  and treatment  of  patients  with  this  neuromuscular
disease.
Materials and methods
This  was  a  national,  multicenter,  epidemiological  study
of  patients  with  a diagnosis  of  diaphragmatic  paralysis  of
unknown  etiology.  The  study  population  was  identified  from
the  Pulmonology  outpatient  consultations  of  9  centers  in
Portugal  over  a  24-month  study  period.  Patients  were con-
secutively  enrolled  if they  were  ≥18  years  of  age,  gave
informed  consent  to  participation,  and fulfilled  one  of  the
following  inclusion  criteria:  diagnosis  of  (unilateral  or  bilat-
eral)  diaphragmatic  paralysis  of  unknown  cause; diagnosis
of  restrictive  lung  disease  (both FVC  [forced  vital capac-
ity]  and TLC  [total  lung  capacity]  < 80%  of  predicted,  or
≥12%  decrease  in VC [vital  capacity]  in  the  supine  posi-
tion),  decreased  maximal  inspiratory  pressure  (IPmax)  or
sniff  nasal  inspiratory  pressure  (SNIP)  (at  least −10 cm  of
H2O  than  predicted)  of  unknown  origin;  diagnosis  of pro-
gressive  chronic  myopathy  with  respiratory  involvement,
particularly  of  the  diaphragm,  with  either inconclusive  mus-
cle  biopsy  or  a diagnosis  based  on  the  generic  definition  of
inclusion  body  myositis.
Patients  were  excluded  from  the study  if they  were
unable  or  unwilling  to provide  informed  consent,  were  tra-
cheostomized  or  pregnant,  required  invasive  mechanical
ventilation,  or  suffered  from  one  of the  following  con-
ditions:  neuromuscular  junction  diseases  (Eaton--Lambert
syndrome,  myasthenia  gravis), myopathies  (polymyositis
and other  mixed  connective  tissue  diseases,  dystrophy
mitochondrial  myopathies,  amyloidosis),  spinal  cord  myelo-
pathy  (cervical  spine  injury,  sarcoidosis,  syringomyelia,
polyomyelitis,  amyotrophic  lateral  sclerosis),  peripheral
neuropathy  [cervical  spine  injury,  mediastinal  tumor,
Guillain--Barré  syndrome,  nutritional  neuropathies  (vitamin
B12  deficiency)  and lead  neuropathy]  or  active  neoplastic
disease.
Information  retrieved  from  patients  included  socio-
demographic  and  clinical  history,  as  well  as physical  exams
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Table  1  Patients’  socio-demographic  characteristics.
n  (%)
Total  no.  of patients  18  (100)
Male 8 (44)
Female  10  (56)
Median  age,  years  (range)  60  (43--81)
Race
Caucasian  18  (100)
Region
Braga 7 (38.9)
Porto 4 (22.0)
Lisbon  3 (16.7)
Coimbra  1 (5.6)
Guarda  1 (5.6)
Leiria 1 (5.6)
Vila Real  1 (5.6)
and  diagnostic  parameters  (including  respiratory  function
tests,  polysomnography,  ultrasound  scan,  chest  radiograph
and  blood  biochemistry),  all  collected  as  part  of  the routine
clinical  practice  for diaphragmatic  paralysis  diagnosis.  Acid
-glucosidase  activity  was  determined  in dried-blood  spots
(DBS)  for  the  diagnosis  of Pompe  disease,17 and a  further
confirmation  through  GAA gene  sequencing  was  done  if the
blood-based  GAA  enzyme  assay  showed  reduced  activity.18
Respiratory  function  tests
Respiratory  function  tests  were  conducted  using  body
plethysmography  with  vital  capacity  determination  in
seated  versus  supine position.  The  single-breath  method
was  used  to  measure  the alveolo-capillary  diffusion  of  CO
(DLCO-SB)  and  thoracic  pressures  were  ascertained  either
by  maximal  inspiratory  pressure  (MIP)  or  by  sniff  nasal
inspiratory  pressure  (SNIP)  followed  by  maximal  expiratory
pressure  (MEP).
Statistical  analysis
Statistical  analysis  was  performed  using  SPSS  15.0  soft-
ware.  Continuous  variables  were  described  as  medians
and  interquartile  ranges,  and categorical  variables  were
described  as  numbers  and  (proportions  with)  percentages.  A
multivariate  analysis  was  performed  to  evaluate  the associ-
ation  between  diaphragmatic  paralysis  and muscle  strength
loss  characteristic  of  Pompe  disease.
Results
A  total  of  18  patients  with  diaphragmatic  paralysis  were
included  in the DIPPER  study  by  the collaborative  Portuguese
centers.  Patients’  socio-demographic  baseline  characteris-
tics  are  reported  in Table 1. Eight  (44%)  patients  were  male
and  10  (56%)  were  female,  the median  age  was  60.8  ±  11.1
(range  43--81)  years,  all  patients  were  Caucasian  and mainly
from  the  North  of  Portugal.
Patient  clinical  history  is summarized  in Table  2.  Briefly,
most  patients  (27.8%)  were  grade  3 (walks  slower  than  most
Table  2  Patients’  clinical  characteristics.
n  (%)
MRC  dyspnea  scale
1 4 (22.2)
2 3 (16.7)
3 5 (27.8)
4 2 (11.1)
Daytime symptoms
Anxiety  8 (44.4)
Irritability  5 (27.8)
Headache  6 (33.3)
Nocturnal  symptoms
Anxiety  6 (33.3)
Snoring  8 (44.4)
Insomnia  6 (33.3)
Non-restorative  sleep  7 (38.9)
Personal history
Comorbidities  (hypertension,
depression,  diabetes,  dyslipidemia,
hypothyroidism)
14  (77.8)
History of  trauma 5  (27.8)
Previous surgeries 8  (44.4)
Family history
Neuromuscular  conditions  2 (11.1)
Metabolic  diseases  (diabetes,
hypertriglyceridemia,  hypothyroidism,
dyslipidemia)
4  (22.2)
Obstructive  sleep  apnea  syndrome  1 (5.6)
Arterial  hypertension  3 (16.7)
Sudden death  2 (11.1)
people  on the  level,  stops  after  a mile  or  so,  or  stops  after
15  min  walking  at own  pace)  in the MRC  dyspnea  scale,  and
57.1%  experienced  anxiety  as  the main  daytime  symptom.
Excessive  daytime  sleepiness  (EDS)  was  measured  through
the  Epworth  sleepiness  scale  (ESS) with  a  median  value  of
7  and  an interquartile  range  of  4--13,  the maximum  value
for  the Epworth  scale  attained  by  any  patient  was  19.  Sev-
eral  nocturnal  symptoms  were  reported,  snoring  (61.5%)  and
non-restorative  sleep  (53.8%)  being  the most frequent.  Arte-
rial  hypertension  was  the  most  frequent  health  precedent,
and  metabolic  diseases  the most  frequent  family  precedent
(n  = 4, 22.2%).
Physical  examination
Overall  physical  status  was  assessed  in 14  patients  by  empir-
ical  observation  with  9  (64.3%)  patients  reported  as  having
good  physical function,  and  5 (35.7%)  reported  to have  mod-
est  physical  function.  Anthropometrics  of  these  patients  are
depicted  in  Table  3.
The  Mallampati  score,  used to  predict  the  ease  of  intu-
bation,  was  assessed  in 13  patients  and  showed  that  most of
them  (n  =  5, 38.5%)  were class  2  (soft  palate,  fauces,  portion
of  uvula),  4  (30.8%)  patients  were class  3 (soft  palate,
base  of uvula),  3 (23.1%)  patients  were  class  1  (soft  palate,
fauces,  uvula,  pillars),  and  only  1 (7.7%)  patient  was  class  4
(hard  palate  only).
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Table  3  Anthropometrics  of  the  14  patients  who performed
the  physical  examination.
Median  (range)
Weight  (kg)  72.5  (48.0--119.0)
Height  (cm)  160.0  (144.0--175.0)
Body surface  (m2)  1.7  (1.4--2.0)
Body mass  index,  BMI  (kg/m2)  29.0  (19.0--37.0)
Blood pressure  (mmHG)
Max  129.0  (105.0--158.0)
Min 80.0  (53.0--104.0)
Oxygen  saturation  (%) 94.0  (84.0--97.0)
Fraction  of  inspired  oxygen  (FiO2) 21.0  (21.0--28.0)
Cervical  perimeter  (m) 35.5  (18.0--45.0)
Neurologic  evaluation  revealed  that  most patients  had
difficulty  getting  up  (n = 8, 61.5%)  and  sitting  (n  =  7, 53.8%).
Concerning  upper  limbs,  cases  of  muscular  atrophy  were
observed  in  3  (23.1%)  patients,  mainly  in arms,  forearms
and  hands,  8  (72.7%)  patients  had  sustained  muscular
strength,  and  10  (76.9%)  patients  had  normal  reflexes.  Con-
cerning  lower  limbs,  muscular  atrophy  was  observed  in 3
(23.1%)  patients,  9  (69.2%)  patients  had  sustained  muscu-
lar  strength,  and  9  (69.2%)  patients  had  normal  reflexes.  An
abnormal  gait  was  identified  in 7  (58.3%)  patients,  mainly
due  to  ataxia  and  weakness  in both  feet  (n = 2, 28.6%,  each),
but  also  due  to  Trendelenburg  walk  in  one  patient,  para-
paresis  in one  patient,  and  as  a consequence  of  bimalleolar
osteoporotic  fracture  in one patient.  Nine  (69.2%)  patients
were  unable  to  run,  with  main  causes  being  fatigue,  dys-
pnea,  and  sequels  from  bimalleolar  osteoporotic  fracture.
Complementary  diagnostic  tests
Fifteen  of  the  18 patients  included  in  this  study  performed
complementary  diagnostic  tests,  including  complete  blood
count  (CBC)  and  blood  biochemistry  (Table  4),  blood  sero-
logy  and  thyroid  function  assessment.  For 88.9%  of  these
patients,  thyroid  function was  within  the normal  range.
One  patient  had positive  serology  for HBV, and  another  for
HCV.  Immunoglobulins  were  within  the normal  range  for  13
patients  and  were  abnormal  for  two  patients,  and  abnormal
levels  of  autoantibodies  were  also  observed  in two  patients.
Creatine  kinase  (CK)  levels  were elevated  in these
patients,  with  a mean  CK  of  249.8  (SD  =  332.9)  U/L,  and  a
median  of  152  (range:  24--1290)  U/L.
The  chest  X-ray  revealed  abnormal  results  in 13  patients,
due  to  (right,  left or  both)  hemidiaphragm  elevation.  In  all
patients  diaphragmatic  paralysis  were  confirmed  by  thoracic
CT  scan  (Fig.  1)  or  thoracic  ultrasound  (Fig.  2) and  changes
in  diaphragmatic  movement  ascertained.
Respiratory  function  tests
Respiratory  function  tests  were mandatory  to  assess  whether
there  was  a  deterioration  of  patients’  respiratory  condi-
tion.  They  may  be  indicative,  for instance,  of  diaphragmatic
weakness  by showing  a difference  between  forced  vital
capacity  (FVC)  in  sitting  and supine  position  --  i.e.  postural
Table  4  Complementary  diagnostic  test  results  for  the  15
patients  who  performed  them.
Median  (range)
CBC
Hemoglobin  (g/100  ml) 13.6  (10.1--16.8)
Leukocyte  count  6725  (1160--11  400)
Neutrophil  count  3820  (824--4964)
Lymphocyte  count  1425  (209--1750)
Platelet count  237  (160--2390)
Blood  biochemistry
Sodium  (mmol/L)  141  (135--147)
Creatinine  (mg/dl) 0.7  (0.5--5.5)
Potassium  (mmol/L) 4.4  (3.4--5.0)
Glucose (mg/DL)  102.5  (81--156)
Protein (g/L)  70  (58--75.4)
Albumin (g/L)  42  (35--62.2)
Creatine  kinase  (CK)  (IU/L)  152  (24--1290)
Calcium (mmol/L) 8.8  (2.3--9.9)
Phosphorus  (mmol/L) 3.2  (0.9--34)
Alkaline  phosphatase 63.5  (34--117)
Gamma-glutamyl  transferase
(GGT)  (IU/L)
28  (8--209)
Alanine aminotransferase  (ALT)
(IU/L)
32  (6--105)
Aspartate  aminotransferase
(AST)  (IU/L)
25.5  (15--94)
Total bilirubin  (mol/L)  9.2  (3.4--23.7)
Direct  bilirubin  (mol/L)  0.2  (0.18--0.21)
Total cholesterol  (mg/dL)  228.5  (119--319)
Thyroglobulin  (ng/dL)  105.5  (2.3--291)
Sedimentation  velocity  (S)  10  (5--80)
Angiotensin-converting  enzyme
(ACE)  (unit/L)
15  (3--67)
IU/L = international units/liters; S = svedberg unit.
drop  --  or  by  a  decreased  mean  inspiratory  pressure  (MIP).
Spirometry  was  used to  measure  how  much  and  how  quickly
patients  could  move  air  out of  their  lungs,  and  lung  function
values  obtained  are shown  in  Table  5, as  well  as  the number
of  patients  in which  this  evaluation  was  collected.
Arterial  blood  gas  analysis  was  performed  at  rest  (FiO2:
21%).  Median  PaO2 was  64.5  (52.0--92.0)  mmHg,  median
PaCO2 was  45.0  (30.0--65.2)  mmHg,  median  O2 satura-
tion  was  92.5  (84.5--97.1)%,  and  median  H2CO3 was  28.8
(23.5--36.0)  meq/L.
Seven  patients  performed  the 6-min  walk  (6MWDT)  test
using  pulse  oxymetry  (SpO2)  monitors.  Six-min  walk  distance
test  (6MWDT)  was  defined  as  the  longest  distance  possible  in
6MWDT  without  encouragement.  Overall,  patients  walked  a
mean  distance  of  334  (SD  =  129.8)  m and  had  a  mean  fall  of
oxygen  saturation  of 7.1%  [91.4%  before  and  84.3%  after  the
test].
Polysomnography  (PSG)  test
PSG results  are shown  in Table 6.
Electromyography  was  preformed  in 6  patients  and
revealed  normal  results  for 4  patients  and  altered  results
for  the other  2.
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Figure  1 Thoracic  CT  scan  showing  right  hemidiaphragmatic  paralysis.
Figure  2  Thoracic  ultrasound  of  patient  with  right  diaphragmatic  paralysis  later  confirmed  as  Pompe.  There  is decreased  right
diaphragm movement  (A)  and  normal  left  diaphragmatic  movement  amplitude  (B).
Table  5  Respiratory  function  tests  (PFTs)  results.
Median  (range)  n
FEV1,  l/s  1.5  (0.48--2.67)  12
FEV1, %  47  (30.0--84.0)  12
FVC 1.7  (0.72--3.25)  12
FVC, %  46.9  (29.0--90.0)  13
Drop in  FVC  from
seated  to  supine
position,  %
30.0  (13.0--60.0)  10
TLC, l 3.3  (2.55--4.27)  5
TLC, %  72.0  (52.9--90.0)  9
RV 1.9  (1.12--2.0)  7
RV, %  92.2  (35.0--104.0)  8
Ratio 82.0  (69.0--98.4)  9
DLCO-SB, %  67.9  (27.8--120.0)  10
IP max,  %  35.0  (32.8--50.6)  11
EP max,  %  76.0  (30.1--135.0)  11
SNIP, %  30.5  (20--41)  2
FEV1 = forced expiratory volume in one second; FVC  = forced
vital capacity; TLC = total lung capacity; RV =  residual vol-
ume; DLCO-SB =  single-breath diffusing capacity of  the lung
for  CO; IP max = decreased maximal inspiratory pressure; EP
max = decreased maximal expiratory pressure; SNIP = sniff nasal
inspiratory pressure; l/s = liters/second; l = liters.
Ref. 46.
Table  6  Polysomnography  (PSG)  test  results.
Median  (range)  n
RDI  7.1  (3.1--11.0)  2
Desaturation  index,  %  12.0  (9.3--17.5)  5
Time with  O2 saturation  <  90%,  %  24.5  (0.5--100.0)  8
Central sleep  apnea,  %  15.0  (10.0--20.0)  2
Obstructive  sleep  apnea,  %  49.5  (0.05--60.0)  4
Mixed apneas,  %  10.0  (10.0--10.0)  2
Hypopnea  15.0  (9.4--61.1)  4
RERAs 0.2  (0.2--0.2)  1
RDI =  respiratory disturbance index; RERA = respiratory effort-
related arousal.
Out  of  the 16  samples  measured  for  dried  blood  spot
(DBS)  acid  -glucosidase,  four tested  positive  for  Pompe
disease,  a  fifth  patient  evidenced  a  small reduction  of
acid  -glucosidase  unconfirmed  by  serum  GAA  activity mea-
surement,  and the  remaining  11  tested  negative.  The  2
remaining  patients  were  tested  for  serum  GAA  activity  (not
DBS)  and  also  tested  negative  for  Pompe.
Discussion
The  late-onset  form  of  Pompe  disease  has  a  heterogeneous
presentation,  mimicking  other  neuromuscular  diseases,
leading  to  diagnostic  challenge.  Clinical  manifestations  vary
in terms  of  organ  involvement,  age  at onset  and  severity,
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and  symptoms  are  often  unspecific  and  may  remain  mild  for
decades,  so that  neither  the patient  nor the doctor  con-
sidered  going  further  with  diagnostic  procedures.  An  early
diagnosis  could  be  relevant  due  to  the chance  of  improving
or  at  least  stabilizing  the  course  of disease  through  enzy-
matic  replacement  therapy  (ERT).19,20
Although  Pompe  disease  is  a rare  condition,  it has
been  reported  in a  number  of different  ethnic  populations,
namely  Caucasian,  Taiwanese,  Korean  and  Japanese.21--31
This  study  is  the first  to  investigate  the  incidence  of  late-
onset  Pompe  disease  in Portugal,  based  on respiratory
signs/symptoms.  One  clinical  study  had  previously  inves-
tigated  and  identified  four  cases of  the juvenile  form  of
the  disease  in  Portuguese  patients,  raising  awareness  of
the  fact  that  Pompe  disease  should be  suspected  in pro-
gressive  myopathies  at  any  age,  especially  those  involving
limb-girdle  and respiratory  muscles  and  in small  infants  with
cardiomyopathy.29
In  the  present  study,  18  patients  with  a  mean  age  of
60.8  ± 11.1  years  and  diaphragmatic  paralysis  were  identi-
fied  and  investigated  for  the late-form  of Pompe  disease.
In  Portugal,  the  diagnosis  recommendations  for  late-onset
Pompe  disease  suggest that  patients  with  a progressive  limb-
girdle  weakness,  fatigue,  cramps  and  muscle  pain  should  be
evaluated  with  creatinine  kinase  (CK)  levels,  electromyog-
raphy,  dynamic  spirometry  and  muscle  biopsy  in inconclusive
cases.16 Suspected  cases  and  those  in which  muscle  biopsy
could  not  allow  other  diagnosis  should  be  screened  for  lyso-
somal  acid--glucosidase  deficiency  with  dried  blood  spot
(DBS),  and  the diagnosis  should  be  confirmed  by determi-
nation  of  lysosomal  acid--glucosidase  activity  in a  second
sample  and  lysosomal  acid--glucosidase  gene  sequenc-
ing.  According  to  this,  5 of  the  18  patients  investigated
evidenced  absence  or  reduction  of  GAA  activity  in the DBS
test.
Muscular  weakness  was  a  common  symptom  in these
patients,  with 61.5%  of patients  showing  difficulty  in getting
up  and  53.8%  in  sitting  down,  in keeping  with  other  studies
that  have  reported  muscular  weakness  as the  most  common
initial  symptom  in late-onset  Pompe  patients.8,32
Laboratory  analysis  revealed  a mean  CK  value  of  249.8
(±332.9;  range:  24--1290)  U/L,  which  is  suggestive  of Pompe
disease,  since  CK  values  are  typically  elevated  (>250  U/L,
equivalent  to  1.5--15  times the  upper  limit  of  normal  in
adults)  in all  forms  of  this  disease.
The  exercise  capacity  (normally  measured  using  the 6-
min  walk  distance  test  [6MWDT])  and pulmonary  function
(forced  vital capacity  [FVC])  are  outcome  measures  com-
monly  used  in  studies  of late-onset  Pompe  disease,  by
registering  changes  in  the  6MWDT  distance  and in VC (mea-
sured  as  percentage  change  in predicted  FVC  [% predicted
FVC]).  In  this  study,  patients  walked  a mean  distance  of
334  ±  129.8  m,  which  is  in  accordance  with  the 246--340  m
distance  reported  by  other  studies  of late-onset  Pompe
patients.33--37 Although  the 6MWDT  is  a  valuable  and  widely
used  functional  measure,  it is  associated  with  consider-
able  inter-  and  intra-investigator  variability,  and  does  not
elucidate  the  mechanisms  behind the  compromised  physi-
cal  function  that  it measures.38 Furthermore,  the  distance
walked  can  be  affected  by  factors  such  as  patient  moti-
vation,  age,  sex,  height,  and  weight  as  well  as  skeletal
problems,39 which  can affect  gait  and  thereby  influence  the
distance  walked, as  we  noticed  in this  study.
FVC  provides  a  simple measure  of pulmonary  function,
and  is  a  widely  used  outcome  measure  in studies  of  patients
with  neuromuscular  disorders.  Because  diaphragm  weakness
often  occurs  early  in the  disease  process and muscle  weak-
ness  may  not be  evident  until  later  in  the disease  course,
respiratory  evaluation  is  extremely  important  for patients
who  may  have  Pompe  disease.  Spirometric  measurement
of  FVC  in both  the  seated and  supine  positions  is  manda-
tory.  A greater  than 10%  drop  in FVC  from  the  seated  to
the  supine  testing  position  is  suggestive  of  diaphragm  weak-
ness  and  should  raise  the  possibility  of  Pompe  disease.40 Both
measurements  should  be made  regardless  of  whether  respi-
ratory  symptoms  are  present.  Because  patients  may  have a
normal  seated  FVC,  the  presence  of  diaphragm  weakness
can be missed  if supine  FVC  is  not  measured.13,41 In this
study,  spirometry  results  revealed  a  30%  median  drop  in FVC
when  patients  switched  from  the upright  to the supine  posi-
tion,  which  is concordant  with  the  diagnosis  of  diaphragm
dysfunction.
Although  not  yet  evaluated  in late-onset  Pompe  disease,
the  sniff  nasal  inspiratory  pressure  (SNIP)  test  allows  ear-
lier  detection  of changes  in respiratory  muscle  strength
than  FVC,  and  might  be a useful  measure  to  assess  these
patients.42
In this study,  we  could  not  find  a  statistically  significant
correlation  between  any  of  the functional  test  results,  for
either pulmonary  function  or  muscle  weakness,  and  Pompe
disease,  but  diaphragm  involvement  was  confirmed  in the
results  for  all the  patients  included.
The  gold  standard  for diagnosis  in  Pompe  disease  is
the  determination  of  partial  or  complete  deficiency  of
GAA  enzyme  activity  in blood  or  fibroblasts.  In this study,
18  patients  with  diaphragmatic  paralysis  were  screened
for  Pompe  disease,  2 through  -glucosidase  serum  activ-
ity  measurements,  16  through  the dried  blood  spot (DBS)
-glucosidase  test,  with  positive  results  for 5 patients.  In
one patient  Pompe  disease  was  not  confirmed  by  subse-
quent  serum  activity  quantifications  (which  were  normal).
In  three  of  the  four  positive  patients  the  diagnosis  of  Pompe
disease  was  established  by  gene  sequencing,  and  all were
recommended  for enzymatic  replacement  therapy  by  the
National  Council  for  Lysosomal  Storage  Diseases.  The  fourth
patient  revealed  only one  previously  identified  mutation
(D91N) related  to  a pseudo  deficiency  of  GAA,  and the  diag-
nosis  for  Pompe  disease  remains  unclear.
Due  to  the low prevalence  and  wide  range  of  symp-
toms,  Pompe  disease  is  often  unrecognized  by  physicians.
Therefore,  the development  of  a diagnostic  methodology
represents  a valuable  tool  to  enhance  the recognition  of
Pompe  disease  by  pulmonologists  and  other  physicians.
The  American  Association  of Neuromuscular  and  Electro-
diagnostic  Medicine  has  developed  an algorithm  to  aid  in
the  diagnosis  of  Pompe  disease,13 and  other  algorithms
have  been  developed  in recent years  to allow  for an  ear-
lier  detection  of  late-onset  Pompe  disease  cases.6,13,43--45
In  patients  presenting  with  diaphragm  paralysis  or  respira-
tory  symptoms  suggestive  of  diaphragm  muscle  involvement,
Pompe  disease  should be included  in the differential
diagnosis  and  patients  should  undergo  further  laboratory,
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electrodiagnostic  and  pulmonary  evaluations,  and imaging
studies,  as  appropriate.
A  simple  DBS test  can improve  both  the  timing  and accu-
racy  of  the  diagnosis,  which  will  lead  to  an improvement  in
the  care  of  patients  who  have  this  progressively  debilitating
neuromuscular  disease.
Limitations
We  were  not able  to  establish  a specific  algorithm  for the
accurate  diagnosis  of  late-onset  Pompe  disease  in this  pop-
ulation.
Another  limitation  of  our  study  was  that the  non Pompe
disease  patients  with  diaphragm  paralysis  did not  have  a
standardized  neurological  evaluation;  these  patients  were
followed  by  Pulmonologist  only and  it may  be  the  case  that
a  multidisciplinary  evaluation  is  warranted  for  better  char-
acterization
Considering  our  primary  objective,  in this  study  we  were
able  to  diagnose  Pompe  disease  in 3 of  our pool  of  18  patients
(16.7%).
Although  results  from  this study  should  be  interpreted
with  caution  due  to  the  small sample  size,  we would like
to  highlight  that Pompe’s  Disease  is  rare,  with  only 27
estimated  cases  undergoing  ERT  in an  overall  national  popu-
lation  of  approximately  10  million,  and  is  our  firm  belief  that
Pompe  should  be  suspected  in all  patients  with  diaphrag-
matic  paralysis  of  unknown  etiology  and that  DBS  should
always  be performed  in these  patients.
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